A fast-growing pharmaceutical company
Substipharm is a private, French healthcare group headquartered in Paris, France and operating in over 80 countries, with direct presence in Europe and Southeast Asia.
We focus on pharmaceuticals and biologics, each operating through a dedicated division.
Our marketed portfolio includes more than 90 different molecules, growing each year thanks to our development pipeline.
With a clear focus on niche and well-differentiated, established products, our business model is two-fold:
- We are experts in developing pharmaceutical dossiers since the company’s foundation in 1995,
- We commercialize our own product portfolio, either directly or through partnerships.
Substipharm’s continued success is led by over 140 passionate employees committed to providing access to quality medicines and biologics for everyone.
This relies on the right blend of expertly driven development projects, targeted acquisition and in-licensing strategy, and disciplined execution of our internationalization plans. Thanks to its nimble, human-scale structure, Substipharm has the agility to execute its numerous R&D and Corporate Development projects, thereby serving its portfolio and geographic expansion, as exemplified by our recent diversification with the acquisition of IMOJEV® vaccine in Asia-Pacific.
Our 2 divisions
Our historical expertise lies in pharmaceuticals, with a recent expansion into the field of vaccines.
Newsroom
11/26/2024
We are thrilled to announce that Substipharm has just completed a new acquisition from Eli Lilly and Company in Japan, Mexico, USA, Australia, and Brazil ! This marks a significant milestone in our journey, further strengthening our internationalization.
